SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease

Neurobiology of Disease

Volumn 73, Issue , 2015, Pages 254-268

  Smith, Ernest S ^a   Jonason, Alan ^a   Reilly, Christine ^a   Veeraraghavan, Janaki ^a   Fisher, Terrence ^a   Doherty, Michael ^a   Klimatcheva, Ekaterina ^a   Mallow, Crystal ^a   Cornelius, Chad ^a   Leonard, John E ^a   Marchi, Nicola ^b   Janigro, Damir ^b   Argaw, Azeb Tadesse ^c   Pham, Trinh ^c   Seils, Jennifer ^a   Bussler, Holm ^a   Torno, Sebold ^a   Kirk, Renee ^a   Howell, Alan ^a   Evans, Elizabeth E ^a   Paris, Mark ^a   Bowers, William J ^a   John, Gareth ^c   Zauderer, Maurice ^a   more..

^a VACCINEX INC   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Blood brain barrier; Monoclonal antibody; Multiple sclerosis; Neuroinflammation; Oligodendrocytes; Remyelination; Semaphorin 4D

Indexed keywords

CD72 ANTIGEN; CLAUDIN 5; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; INTERLEUKIN 17; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2503; MONOCLONAL ANTIBODY 2B8; MONOCLONAL ANTIBODY 67 2; PLEXIN; PLEXIN B1; PLEXIN B2; RECOMBINANT BETA INTERFERON; SEMAPHORIN; SEMAPHORIN 4D; TRANSCRIPTION FACTOR NKX2.2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; SEMA4D PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY DETECTION; ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL DIFFERENTIATION; CELL DISRUPTION; CELL SURVIVAL; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMYELINATION; DISEASE SEVERITY; DRUG BRAIN LEVEL; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H3N2); LYMPHOCYTE PROLIFERATION; MALE; MEMBRANE DAMAGE; MEMBRANE PERMEABILITY; MICROGLIA; MIGRATION INHIBITION; MOUSE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REMYELINIZATION; SIGNAL TRANSDUCTION; SPLEEN CELL; TIGHT JUNCTION; VIRAL CLEARANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; IMMUNOLOGY; METABOLISM; OLIGODENDROGLIA; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MALE; MICE; MICE, INBRED C57BL; OLIGODENDROGLIA; RATS; RATS, SPRAGUE-DAWLEY; SEMAPHORINS;

EID: 84908626377     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.10.008     Document Type: Article

References (54)

1. Adams C.W. Pathology of multiple sclerosis: progression of the lesion. Br. Med. Bull. 1977, 33:15-20.
2. Aslam M., Ahmad N., Srivastava R., Hemmer B. TNF-alpha induced NFkappaB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 2012, 57:269-275.
3. Axtell R.C., deJong B.A., Boniface K., van der Voort L.F., Bhat R., DeSarno P., et al. T helper Type 1 and 17 cells determine efficacy of interferon-B in MS & experimental encephalomyelistis. Nat. Med. 2010, 16:406-412.
4. Azzarelli R., Pacary E., Garg R., Garcez P., van den Berg D., Riou P., et al. An antagonistic interaction between PlexinB2 and Rnd3 controls RhoA activity and cortical neuron migration. Nat. Commun. 2014, 5:3405.
5. Basile J.R., Barac A., Zhu T., Guan K.L., Gutkind J.S. Class IV semaphorins promote angiogenesis by stimulating Rho-initiated pathways through plexin-B. Cancer Res. 2004, 64:5212-5224.
6. Basile J.R., Afkhami T., Gutkind J.S. Semaphorin 4D/plexin-B1 induces endothelial cell migration through the activation of PYK2, Src, and the phosphatidylinositol 3-kinase-Akt pathway. Mol. Cell. Biol. 2005, 25:6889-6898.
7. Basile J.R., Gavard J., Gutkind J.S. Plexin-B1 utilizes RHOA and ROK to promote the integrin-dependent activation of AKT and ERK, and endothelial cell motility. J. Biol. Chem. 2007, 282:34888-34895.
8. Berger J.R. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf. 2010, 33:969-983.
9. Brinkmann V., Billich A., Baumruker T., Heining P., Schmouder R., Francis G., et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 2010, 9:883-897.
10. Bruckener K.E., el, B.A., Galla H.J., Schmidt M.A. Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP. J Cell Sci. 2003, 116:1837-1846.
11. Ch'ng E.S., Kumanogoh A. Roles of Sema4D and Plexin-B1 in tumor progression. Mol. Cancer 2010, 9:251.
12. Conrotto P., Valdembri D., Corso S., Serini G., Tamagnone L., Comoglio P.M., et al. Sema4D induces angiogenesis through Met recruitment by Plexin B1. Blood 2005, 105:4321-4329.
13. Cucullo L., Marchi N., Hossain M., Janigro D. A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J. Cereb. Blood Flow Metab. 2011, 31:767-777.
14. Delaire S., Billard C., Tordjman R., Chedotal A., Elhabazi A., Bensussan A., et al. Biological activity of soluble CD100. II. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration. J. Immunol. 2001, 166:4348-4354.
15. Errede M., Girolamo F., Ferrara G., Strippoli M., Morando S., Boldrin V., et al. Blood-brain barrier alterations in the cerebral cortex in experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 2012, 71:840-854.
16. Evans E.E., Henn A.D., Jonason A., Paris M.J., Schiffhauer L.M., Borrello M.A., et al. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer. Mol. Cancer Ther. 2006, 5:2919-2930.
17. Giger R.J., Hollis E.R., Tuszynski M.H. Guidance molecules in axon regeneration. Cold Spring Harb. Perspect. Biol. 2010, 2:a001867.
18. Giordano S., Corso S., Conrotto P., Artigiani S., Gilestro G., Barberis D., et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 2002, 4:720-724.
19. Giraudon P., Vincent P., Vuaillat C., Verlaeten O., Cartier L., Marie-Cardine A., et al. Semaphorin CD100 from activated T lymphocytes induces process extension collapse in oligodendrocytes and death of immature neural cells. J. Immunol. 2004, 172:1246-1255.
20. Giraudon P., Vincent P., Vuaillat C. T-cells in neuronal injury and repair: semaphorins and related T-cell signals. Neruomol. Med. 2005, 7:207-216.
21. Gleichmann E., Kimber I., Purchase I.F. Immunotoxicology: suppressive and stimulatory effects of drugs and environmental chemicals on the immune system. A discussion. Arch. Toxicol. 1989, 63:257-273.
22. Hall K.T., Boumsell L., Schultze J.L., Boussiotis V.A., Dorfman D.M., Cardoso A.A., et al. Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:11780-11785.
23. Hohlfeld R., Barkhof F., Polman C. Future clinical challenges in multiple sclerosis: relevance to sphingosine 1-phosphate receptor modulator therapy. Neurology 2011, 76:S28-S37.
24. Ishida I., Kumanogoh A., Suzuki K., Akahani S., Noda K., Kikutani H. Involvement of CD100, a lymphocyte semaphorin, in the activation of the human immune system via CD72: implications for the regulation of immune and inflammatory responses. Int. Immunol. 2003, 15:1027-1034.
25. Jager A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 2009, 183:7169-7177.
26. Kappos L., Radue E.W., O'Connor P., Polman C., Hohlfeld R., Calabresi P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010, 362:387-401.
27. Kikutani H., Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat. Rev. Immunol. 2003, 3:159-167.
28. Kumanogoh A., Kikutani H. The CD100-CD72 interaction: a novel mechanism of immune regulation. Trends Immunol. 2001, 22:670-676.
29. Kumanogoh A., Watanabe C., Lee I., Wang X., Shi W., Araki H., et al. Identification of CD72 as a lymphocyte receptor for the class IV semaphorin CD100: a novel mechanism for regulating B cell signaling. Immunity 2000, 13:621-631.
30. Kumanogoh A., Suzuki K., Ch'ng E., Watanabe C., Marukawa S., Takegahara N., et al. Requirement for the lymphocyte semaphorin, CD100, in the induction of antigen-specific T cells and the maturation of dendritic cells. J. Immunol. 2002, 169:1175-1181.
31. Leech S., Kirk J., Plumb J., McQuaid S. Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis. Neuropathol. Appl. Neurobiol. 2007, 33:86-98.
32. Levine J.M., Reynolds R. Activation and proliferation of endogenous oligodendrocyte precursor cells during ethidium bromide-induced demyelination. Exp. Neurol. 1999, 160:333-347.
33. Liang X., Draghi N.A., Resh M.D. Signaling from integrins to Fyn to Rho family GTPases regulates morphologic differentiation of oligodendrocytes. J. Neurosci. 2004, 24:7140-7149.
34. Mi S., Hu B., Hahm K., Luo Y., Kam Hui E.S., Yuan Q., et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat. Med. 2007, 13:1228-1233.
35. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
36. Moreau-Fauvarque C., Kumanogoh A., Camand E., Jaillard C., Barbin G., Boquet I., et al. The transmembrane semaphorin Sema4D/CD100, an inhibitor of axonal growth, is expressed on oligodendrocytes and upregulated after CNS lesion. J. Neurosci. 2003, 23:9229-9239.
37. Niederost B., Oertle T., Fritsche J., McKinney R.A., Bandtlow C.E. Nogo-A and myelin-associated glycoprotein mediate neurite growth inhibition by antagonistic regulation of RhoA and Rac1. J. Neurosci. 2002, 22:10368-10376.
38. Okuno T., Nakatsuji Y., Moriya M., Takamatsu H., Nojima S., Takegahara N., et al. Roles of Sema4D-Plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J. Immunol. 2010, 184:1499-1506.
39. Ozawa K., Suchanek G., Breitschopf H., Bruck W., Budka H., Jellinger K., et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994, 117:1311-1322.
40. Pavelko K.D., van Engelen B.G., Rodriguez M. Acceleration in the rate of CNS remyelination in lysolecithin-induced demyelination. J. Neurosci. 1998, 18:2498-2505.
41. Pierson E., Simmons S.B., Castelli L., Goverman J.M. Mechanisms regulating regional localization of inflammation during CNS autoimmunity. Immunol. Rev. 2012, 248:205-215.
42. Prineas J. Pathology of the early lesion in multiple sclerosis. Hum. Pathol. 1975, 6:531-554.
43. Shi W., Kumanogoh A., Watanabe C., Uchida J., Wang X., Yasui T., et al. The class IV semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice. Immunity 2000, 13:633-642.
44. Soon D., Tozer D., Altmann D., Tofts P., Miller D. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Mult. Scler. 2007, 13:884-894.
45. Suzuki K., Kumanogoh A., Kikutani H. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 2008, 9:17-23.
46. Tamagnone L., Artigiani S., Chen H., He Z., Ming G.I., Song H., et al. Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates. Cell 1999, 99:71-80.
47. Taniguchi Y., Amazaki M., Furuyama T., Yamaguchi W., Takahara M., Saino O., et al. Sema4D deficiency results in an increase in the number of oligodendrocytes in healthy and injured mouse brains. J. Neurosci. Res. 2009, 87:2833-2841.
48. Vos C.M., Geurts J.J., Montagne L., van Haastert E.S., Bo L., van, d., V, et al. Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis 2005, 20:953-960.
49. Watanabe M., Hadzic T., Nishiyama A. Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination. Glia 2004, 46:311-322.
50. Weber M.S., Menge T., Lehmann-Horn K., Kronsbein H.C., Zettl U., Sellner J., et al. Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects. Curr. Pharm. Des. 2012, 18:209-219.
51. Wolswijk G. Oligodendrocyte survival, loss and birth in lesions of chronic-stage multiple sclerosis. Brain 2000, 123:105-115.
52. Yang Y.H., Zhou H., Binmadi N.O., Proia P., Basile J.R. Plexin-B1 activates NF-kappaB and IL-8 to promote a pro-angiogenic response in endothelial cells. PLoS ONE 2011, 6:e25826.
53. Zhu L., Bergmeier W., Wu J., Jiang H., Stalker T.J., Cieslak M., et al. Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:1621-1626.
54. Zlokovic B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat. Rev. Neurosci. 2011, 12:723-738.